Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jasper Therapeutics ( (JSPR) ) just unveiled an announcement.
On June 14, 2025, Jasper Therapeutics reported positive results from the 180mg cohort of its SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adult participants with chronic inducible urticaria. The study showed that 92% of participants achieved a complete response, and 100% achieved a clinical response, with no serious adverse events reported. The results demonstrate briquilimab’s potential to rapidly deliver robust and durable control of urticaria symptoms, supporting its development as a treatment for mast cell-driven diseases.
The most recent analyst rating on (JSPR) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on Jasper Therapeutics stock, see the JSPR Stock Forecast page.
Spark’s Take on JSPR Stock
According to Spark, TipRanks’ AI Analyst, JSPR is a Underperform.
Jasper Therapeutics faces significant financial challenges with a lack of revenue and ongoing losses, leading to a low financial performance score. The technical analysis indicates bearish momentum, and the negative valuation metrics highlight the stock’s unattractiveness. Without earnings call data or notable corporate events, the overall outlook remains concerning.
To see Spark’s full report on JSPR stock, click here.
More about Jasper Therapeutics
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell-driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma.
Average Trading Volume: 195,117
Technical Sentiment Signal: Sell
Current Market Cap: $83.82M
Find detailed analytics on JSPR stock on TipRanks’ Stock Analysis page.